CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - April 2024
2 Apr 2024: Datopotamab deruxtecan BLA accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
- AstraZeneca and Daiichi Sankyo’s BLA for Datopotamab deruxtecan in HR-positive, HER2-negative breast cancer accepted in the US
- Datopotamab deruxtecan showed significant improvement in progression-free survival (PFS) compared to chemotherapy in Phase III trial
- If approved, Datopotamab deruxtecan could offer an alternative to chemotherapy for patients with advanced breast cancer
- Safety profile consistent with other trials; no new safety concerns identified
- Additional BLA for Datopotamab deruxtecan under review for non-small cell lung cancer; global clinical trials ongoing for multiple cancer types
